Small molecule · Antagonist of dopamine D2 receptor (DRD2) and serotonin 5-HT2 receptor (HTR2A) · developed by Janssen Pharms
ApprovedFDA, Dec 1993
1Registered trials
What is Risperidone?
Risperidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2 receptors, with additional receptor antagonism that may account for other effects. It is used in the treatment of schizophrenia, and an extended-release subcutaneous injectable formulation is studied in schizophrenia.
Summary written with AI from the sources listed at the end of this page.
Bipolar I disorder (Rykindo Extended-Release Microspheres)
From the indications section of the FDA label (version of May 26, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.